In Peutz Jeghers syndrome, Tuberous Sclerosis, and other diseases where PTEN is inactivated, the use of rapamycin as a clinical means to reverse the effect of elevated mTOR activity is an attractive option (Inoki et al, 2005a). Here, PTEN is linked to tuberous sclerosis.